Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory ...
Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...